Platform Clinical Study for Conquering Scleroderma

NCT06195072 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Disease Due to Systemic Disease
Scleroderma

Interventions

DRUG: Amlitelimab
DRUG: BI 1015550 (Nerandomilast)
DRUG: Placebo

Sponsor

Scleroderma Research Foundation, Inc.

Collaborators

[object Object]
[object Object]